Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).
This study has been completed.
Sponsor:
IBSA Institut Biochimique SA
Information provided by:
IBSA Institut Biochimique SA
ClinicalTrials.gov Identifier:
NCT00335894
First received: June 9, 2006
Last updated: March 9, 2010
Last verified: December 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and the other the reference drug hMG (Menopur, Ferring Pharmaceuticals, Inc.).
Condition | Intervention | Phase |
---|---|---|
Infertility |
Drug: hMG-IBSA |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment |
Official Title: | A Prospective, Randomized, Investigator-blind, Controlled, Clinical Study of Phase III on the Efficacy and Tolerability of hMG-IBSA (IBSA) vs Menopur (Ferring) Administered s.c. in Women Undergoing COH in an ART Programme (IVF) |
Resource links provided by NLM:
Further study details as provided by IBSA Institut Biochimique SA:
Primary Outcome Measures:
- total number of oocytes retrieved 34 - 36 hours after hCG administration.
Secondary Outcome Measures:
- Total dose of hMG (IU); number of days of hMG stimulation and stimulation duration; cancellation rate with reasons; 17β-estradiol (E2) serum concentration; number of follicles >16 mm.
- number of mature oocytes and inseminated oocytes; fertilization rate.
- embryo score; number of transferred embryos; implantation rate, number of transferred embryos; clinical pregnancy rate
- Tolerability evaluation
Estimated Enrollment: | 144 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | March 2009 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
The purpose of the study is to evaluate the clinical efficacy and general tolerability of two different subcutaneous hMG preparations (hMG-IBSA, IBSA vs Menopur, Ferring Pharmaceuticals, Inc.) when administered to patients undergoing controlled ovarian stimulation for IVF.
Eligibility
Ages Eligible for Study: | 18 Years to 36 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic sperm injection) and with the following characteristics:
- Voluntary given informed consent to study participation in writing encompassing consent to data recording and verification procedures;
- > 18/= and < 37 years old;
- BMI between 18 and 28 kg/m2;
- Less than 3 previous completed IVF cycles;
- Basal FSH level less than 10 IU/L once within 6 months prior to the study;
- Within 12 month of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, or sonohysterogram, or hysteroscopic examination or TVUS;
- Normal or clinically insignificant haematology and blood chemistry values.
Exclusion Criteria:
- Primary ovarian failure or women known as poor responders;
- Signs of PCO, according to the Rotterdam Criteria;
- At least one ovary inaccessible for oocyte retrieval;
- One or more ovarian cysts > 10 mm;
- Hydrosalpinx that have not been surgically removed or ligated;
- Stage III or IV endometriosis;
- Patients affected by pathologies associated with any contraindication of being pregnant;
- Hypersensitivity to the study medication;
- Abnormal bleeding of undetermined origin;
- Uncontrolled thyroid or adrenal dysfunction;
- Neoplasias;
- PAP smear III within the last 2 years;
- Severe impairment of the renal and/or hepatic functions;
- Lactation;
- Hyperprolactinaemia;
- Participation in a concurrent clinical trial or in another trial within the past four weeks;
- Use of concomitant medication that might interfere with study evaluations.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00335894
Locations
Italy | |
Università degli Studi di Bologna | |
Bologna, Italy, 40138 | |
Università degli Studi di Napoli Federico II | |
Napoli, Italy, 80131 |
Sponsors and Collaborators
IBSA Institut Biochimique SA
Investigators
Study Director: | Giuseppe De Placido, Prof | Federico II University |
More Information
Publications:
Keywords provided by IBSA Institut Biochimique SA:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
Publications:
ClinicalTrials.gov Identifier: | NCT00335894 History of Changes |
Other Study ID Numbers: | 04I/HMG10 |
Study First Received: | June 9, 2006 |
Last Updated: | March 9, 2010 |
Health Authority: | Italy: The Italian Medicines Agency |
Keywords provided by IBSA Institut Biochimique SA:
Infertility IVF ART hMG |
Additional relevant MeSH terms:
Infertility Genital Diseases, Male Genital Diseases, Female |
ClinicalTrials.gov processed this record on October 16, 2012